Wakelee H., Liberman M., Kato T., Tsuboi M., Lee S.-H., Gao S., Chen K.-N., Dooms C., Majem M., Eigendorff E., Martinengo G.L., Bylicki O., Rodríguez-Abreu D., Chaft J.E., Novello S., Yang J., Keller S.M., Samkari A., Spicer J.D.. Perioperative Pembrolizumab for Early-Stage Non-Small-Cell Lung Cancer. NEW ENGLAND JOURNAL OF MEDICINE. 2023; 389(6)DOI:10.1056/NEJMoa2302983. PMID:37272513. IF:96.300(Q1/1D).

Tibau A., Martínez M.T., Ramos M., De La Cruz-Merino L., Santaballa A., O’Connor M., Martínez-Jañez N., Moreno F., Fernández I., Virizuela J.A., Alarcón J., de La Haba-Rodríguez J., Sánchez-Rovira P., Albacar C.R., Bueno Muiño C., Kelly C., Casas M., Bezares S., Rosell L., Albanell J.. Quality of life with palbociclib plus fulvestrant versus placebo plus fulvestrant in postmenopausal women with endocrine-sensitive hormone receptor-positive and HER2-negative advanced breast cancer: patient-reported outcomes from the FLIPPER trial. Therapeutic Advances in Medical Oncology. 2023; 15DOI:10.1177/17588359221148921. PMID:36743520. IF:4.300(Q2/3D).

Jimenez-Fonseca P., Foy V., Raby S., Carmona-Bayonas A., Macía-Rivas L., Arrazubi V., Cacho Lavin D., Hernandez San Gil R., Custodio A., Cano J.M., Fernández Montes A., Mirallas O., Macias Declara I., Vidal Tocino R., Visa L., Limón M.L., Pimentel P., Martínez Lago N., Sauri T., Martín Richard M., Mangas M., Gil Raga M., Calvo A., Reguera P., Granja M., Martín Carnicero A., Hernández Pérez C., Cerdá P., Gomez Gonzalez L., Garcia Navalon F., Pacheco Barcia V., Gutierrez Abad D., Ruiz Martín M., Weaver J., Mansoor W., Gallego J.. The AGAMENON-SEOM model for prediction of survival in patients with advanced HER2-positive oesophagogastric adenocarcinoma receiving first-line trastuzumab-based therapy. Therapeutic Advances in Medical Oncology. 2023; 15DOI:10.1177/17588359231157641. PMID:36895850. IF:4.300(Q2/3D).

Martin-Broto J., Martinez-Garcia J., Moura D.S., Redondo A., Gutierrez A., Lopez-Pousa A., Martinez-Trufero J., Sevilla I., Diaz-Beveridge R., Solis-Hernandez M.P., Carnero A., Perez M., Marcilla D., Garcia-Foncillas J., Romero P., Fernandez-Jara J., Lopez-Lopez D., Arribas I., Hindi N.. Phase II trial of CDK4/6 inhibitor palbociclib in advanced sarcoma based on mRNA expression of CDK4/ CDKN2A. Signal Transduction and Targeted Therapy. 2023; 8(1)DOI:10.1038/s41392-023-01661-8. PMID:37875500. IF:40.800(Q1/1D).

Hwang, TJ, Trinh, QD, Tibau, A, Vokinger, KN. Reforms to accelerated approval of new medicines: long overdue. LANCET. 2022; 400(10349)DOI:10.1016/S0140-6736(22)01276-4. PMID:35835129. IF:168.900(Q1/1D).

Lindskog, M, Laurell, A, Kjellman, A, Melichar, B, Rey, PM, Zielinski, H, Villacampa, F, Bigot, P, Zoltan, B, Parikh, O, Alba, DV, Jellvert, D, Flasko, T, Gallardo, E, Caparros, MJR, Purkalne, G, Suenaert, P, Karlsson-Parra, A, Ljungberg, B. Ilixadencel, a Cell-based Immune Primer, plus Sunitinib Versus Sunitinib Alone in Metastatic Renal Cell Carcinoma: A Randomized Phase 2 Study. European Urology Open Science. 2022; 40DOI:10.1016/j.euros.2022.03.012. PMID:35638086. IF:2.500(Q3/6D).